Prospective follow-up study of golimumab treatment in psoriatic arthritis

Prospective follow-up study of golimumab treatment in psoriatic arthritis - Golimumab in psoriatic arthritis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37425

Enrollment

100

Registered

2012-02-20

Start date

2012-02-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriatic arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients with psoriatic arthritis in whom golimumab treatment is started written informed consent

Exclusion criteria

Exclusion criteria: contraindications against golimumab treatment

Design outcomes

Primary

Measure	Time frame
- ACR20 response: 20% improvement or 10 point decrease on 100mm VASscales - PASI improvement - MDA status	—

Secondary

Measure	Time frame
-The number of adverse events (infections, malignancies, mortality) - LEI Improvement -Number of digits with dactylitis -Number of nails with nail psoriasis -ESR and/or CRP -The lipid profile -inflammation processes -Relation between genetic polymorphisms and the efficacy of golimumab -Radiographic progression -Changes in bone mineral density.	—

Countries

Netherlands

Outcome results